Background: Infection with high-risk genotypes of Human papillomaviruses (HPV) is the major factor in the pathogenesis of cervical cancer. HPV genotypes 16,18,31,45 causes 90 % of cervical cancer and these high-risk HPV genotypes cause nearly 100% of invasive cervical cancer. Cervical cancer can be prevented by vaccination against HPV high-risk genotypes. Effective cancer treatment programmes can improve survival rates for cervical cancer. Materials and Method: This study was aimed to evaluate the prevalence of HPV high-risk genotypes, so that high-risk individuals could be targeted, and specific genotypes associated with cervical cancer to be included in the vaccine preparations. Symptomatic patients visiting Gynaecology OPD of tertiary care hospital in India were recruited and Conventional PCR assay was done for detection of High-Risk genotypes of HPV causing cervical cancer. Statistical Analysis was done with PASW 18.0 (Predictive Analysis Software) by statistician. P value obtained by Chi Square test and p<0.05 was considered significant. Results: Out of the 72 symptomatic cases PCR was positive in 17 patients (23.6 %). In asymptomatic cases PCR positivity was 10.7%. Out of the100 patient’s PCR was positive in 20% of the cases. Among the symptomatic PCR was positive in 17 cases. HPV -16 (9.7 %) was the most common genotype among them. Infection with multiple genotypes 16 and 18 was positive in 6 cases (8.3 %), HPV -31 &45 was positive in 2 cases (2.8 %.) HPV -18 was positive in 2 cases (2.8 %) Among the asymptomatic HPV 16 in one case (3.5%), HPV-31 in one case (3.5 %), HPV -31&45 in one case (3.5 %). Conclusion: Our study results suggested inclusion of HPV 31 and 45 genotypes in HPV vaccine available and marketed in India.